Administration of the synthetic STING agonist ADU-S100 leads to durable anti-tumor immunity via promoting T-cell responses

Explore related products in the following collection:

Poster Abstracts - C717

Related Products

Thumbnail for Exogenous control of CAR-T performance with RNA-based gene regulation

Exogenous control of CAR-T performance with RNA-based gene regulation

Thumbnail for Site-specific conjugation of novel flourophores and tags to accelerate immunotherapy discovery and development

Site-specific conjugation of novel flourophores and tags to accelerate immunotherapy discovery and development

Thumbnail for Tanapoxvirus expressing interleukin-2 is capable of human melanoma regression in the absence of T cells

Tanapoxvirus expressing interleukin-2 is capable of human melanoma regression in the absence of T cells

Thumbnail for Characterization of SB 11285 as a novel STING agonist for Immuno-oncology

Characterization of SB 11285 as a novel STING agonist for Immuno-oncology

Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.